DrugPatentWatch Database Preview
XERAVA Drug Profile
» See Plans and Pricing
When do Xerava patents expire, and what generic alternatives are available?
Xerava is a drug marketed by Tetraphase Pharms and is included in one NDA. There are two patents protecting this drug.
This drug has seventy patent family members in thirty countries.
The generic ingredient in XERAVA is eravacycline dihydrochloride. Additional details are available on the eravacycline dihydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Xerava
Xerava will be eligible for patent challenges on August 27, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 28, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for XERAVA
| International Patents: | 70 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 17 |
| Patent Applications: | 22 |
| Drug Prices: | Drug price information for XERAVA |
| What excipients (inactive ingredients) are in XERAVA? | XERAVA excipients list |
| DailyMed Link: | XERAVA at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for XERAVA
Generic Entry Date for XERAVA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for XERAVA
International Patents for XERAVA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1193412 | Get Started for $10 |
| Norway | 2019010 | Get Started for $10 |
| Slovenia | 2323972 | Get Started for $10 |
| Lithuania | PA2019009 | Get Started for $10 |
| Serbia | 53003 | Get Started for $10 |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for XERAVA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2323972 | CA 2019 00009 | Denmark | Get Started for $10 | PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209 |
| 2323972 | C20190009 00277 | Estonia | Get Started for $10 | PRODUCT NAME: ERAVATSUEKLIIN;REG NO/DATE: EU/1/18/1312 24.09.2018 |
| 2323972 | CR 2019 00009 | Denmark | Get Started for $10 | PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209 |
| 2323972 | LUC00107 | Luxembourg | Get Started for $10 | PRODUCT NAME: ERAVACYCLINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924 |
| 2323972 | 19C1012 | France | Get Started for $10 | PRODUCT NAME: ERAVACYCLINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/18/1312 20180924 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
